Edward Gelmann
Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Edward Gelmann

Oncology
Banner Health
Banner-University Medical Center Tucson Campus
1625 North Campbell Avenue, 
Tucson, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Banner Health
Banner-University Medical Center Tucson Campus
1625 North Campbell Avenue, 
Tucson, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

I'm actively involved in oncology patient care, in pre- and postdoctoral education, and in teaching graduate students, house staff and fellows.

Dr. Gelmann is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Urothelial Cancer, Familial Prostate Cancer, and Bladder Cancer.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Stanford University, 1976
Residency
University of Chicago Pritzker School of Medicine, Internal Medicine, 1978
Specialties
Oncology
Licenses
Internal Medicine in NY
Board Certifications
American Board Of Internal Medicine/Medical Oncology
American Board Of Internal Medicine
Fellowships
National Cancer Institute, NIH, Medical Oncology, 1981
Hospital Affiliations
Banner - University Medical Center Tucson
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Banner-University Medical Center Tucson Campus
1625 North Campbell Avenue, Tucson, AZ 85719
Call: 520-694-0111
Other Locations
University of Arizona Cancer Center
1891 West Orange Grove Road, Building 1, Tucson, AZ 85704
Call: 520-694-2873
University of Arizona Cancer Center
3838 North Campbell Avenue, Building 1, Tucson, AZ 85719
Call: 520-694-2873

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
A Phase 2 Single-Arm Multicenter Study of Entinostat in Patients With Relapsed or Refractory Abdominal Neuroendocrine (NE) Tumors
A Phase 2 Single-Arm Multicenter Study of Entinostat in Patients With Relapsed or Refractory Abdominal Neuroendocrine (NE) Tumors
Enrollment Status: Terminated
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Entinostat
Study Phase: Phase 2
View 4 Less Clinical Trials

16 Total Publications

Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.
Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.
Journal: The oncologist
Published: April 07, 2024
View All 16 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Donald J. Brooks
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Donald J. Brooks
Hematology Oncology | Oncology | Hematology

Tmc Medical Network

2070 W Rudasill Rd, Suite 130, 
Tucson, AZ 
 (6.3 miles away)
520-420-2520
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Donald Brooks is a Hematologist Oncology specialist and an Oncologist in Tucson, Arizona. Dr. Brooks is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Non-Hodgkin Lymphoma, and Lung Cancer. Dr. Brooks is currently accepting new patients.

Alejandro R. Boiles
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Alejandro R. Boiles
Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Alejandro R. Boiles
Oncology

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
 (0.3 miles away)
520-694-2873
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

I am an avid moviegoer and attempt to expand on all genres with a high appreciation for historical and accurate storytelling. I am fascinated by the Arizona landscape and enjoy spending my time exploring. I am always in search for a unique gastronomy experience, Tucson's rich culture makes this easy to obtain. Dr. Boiles is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Urothelial Cancer, and Familial Wilms Tumor 2.

Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Richard K. Rosenberg
Hematology Oncology | Oncology | Hematology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Richard K. Rosenberg
Hematology Oncology | Oncology | Hematology

Tmc Medical Network

5301 E Grant Rd, 
Tucson, AZ 
 (3.9 miles away)
520-324-4230
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Rosenberg is a Hematologist Oncology specialist and an Oncologist in Tucson, Arizona. Dr. Rosenberg is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Rosenberg is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gelmann's expertise for a condition
ConditionClose
    • Distinguished
    • Bladder Cancer
      Dr. Gelmann is
      Distinguished
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Familial Prostate Cancer
      Dr. Gelmann is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Muscle Invasive Bladder Cancer
      Dr. Gelmann is
      Distinguished
      . Learn about Muscle Invasive Bladder Cancer.
      See more Muscle Invasive Bladder Cancer experts
    • Non-Muscle Invasive Bladder Cancer
      Dr. Gelmann is
      Distinguished
      . Learn about Non-Muscle Invasive Bladder Cancer.
      See more Non-Muscle Invasive Bladder Cancer experts
    • Prostate Cancer
      Dr. Gelmann is
      Distinguished
      . Learn about Prostate Cancer.
      See more Prostate Cancer experts
    • Urothelial Cancer
      Dr. Gelmann is
      Distinguished
      . Learn about Urothelial Cancer.
      See more Urothelial Cancer experts
      • Experienced
      • Adult Soft Tissue Sarcoma
        Dr. Gelmann is
        Experienced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • Choriocarcinoma
        Dr. Gelmann is
        Experienced
        . Learn about Choriocarcinoma.
        See more Choriocarcinoma experts
      • Chromophobe Renal Cell Carcinoma
        Dr. Gelmann is
        Experienced
        . Learn about Chromophobe Renal Cell Carcinoma.
        See more Chromophobe Renal Cell Carcinoma experts
      • Clear Cell Sarcoma
        Dr. Gelmann is
        Experienced
        . Learn about Clear Cell Sarcoma.
        See more Clear Cell Sarcoma experts
      • Familial Wilms Tumor 2
        Dr. Gelmann is
        Experienced
        . Learn about Familial Wilms Tumor 2.
        See more Familial Wilms Tumor 2 experts
      • Neuroendocrine Tumor
        Dr. Gelmann is
        Experienced
        . Learn about Neuroendocrine Tumor.
        See more Neuroendocrine Tumor experts
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2026 All Rights Reserved